Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Resonance Health's Enterprise Value is A$23.31 Mil.
Resonance Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.55 Mil. Therefore, Resonance Health's EV-to-EBIT ratio for today is 42.37.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Resonance Health's Enterprise Value is A$23.31 Mil.
Resonance Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.50 Mil. Therefore, Resonance Health's EV-to-EBITDA ratio for today is 15.50.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Resonance Health's Enterprise Value is A$23.31 Mil.
Resonance Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$13.84 Mil. Therefore, Resonance Health's EV-to-Revenue ratio for today is 1.68.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Resonance Health's Enterprise Value is A$23.31 Mil.
Resonance Health's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.15 Mil. Therefore, Resonance Health's EV-to-FCF ratio for today is -152.33.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Resonance Health (ASX:RHT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Resonance Health's current Enterprise Value is A$23.31 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.55 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Resonance Health's current Enterprise Value is A$23.31 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.50 Mil.
Resonance Health's current Enterprise Value is A$23.31 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$13.84 Mil.
Resonance Health's current Enterprise Value is A$23.31 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.42 Mil.
Resonance Health's current Enterprise Value is A$23.31 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health Enterprise Value Related Terms
Resonance Health Enterprise Value Historical Data
* Premium members only.
The historical data trend for Resonance Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: Enterprise Value Comparison
For the Health Information Services subindustry, Resonance Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Enterprise Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Resonance Health's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Resonance Health's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Enterprise Value of A$23.31 Mil as of Jun. 24, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Resonance Health and its competitors.
Is Resonance Health's Enterprise Value too high?
Resonance Health's current Enterprise Value is A$23.31 Mil.
How does Resonance Health's Enterprise Value compare to VEEV and BTSG?
Resonance Health's Enterprise Value of A$23.31 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Healthcare Providers & Services company?
A good Enterprise Value depends on the Healthcare Providers & Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Resonance Health and its competitors. Resonance Health's current Enterprise Value is A$23.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current Enterprise Value is A$23.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Enterprise Value is A$23.31 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 